1 December 2008 - Ark Therapeutics Group plc today announces that the Marketing Authorisation Application for Cerepro, Ark’s novel gene-based therapy for operable malignant glioma (brain cancer), has been filed with the European medicines regulatory agency (EMEA).
The details can be read here.
No comments:
Post a Comment